1: AID groups
OtherClinical and Biological investigations
NCT Number: NCT02466217
The family of inflammatory/autoimmune systemic diseases (IAD) form a continuum from pure inflammatory diseases to pure autoimmune diseases, encompassing a large panel of inflammatory diseases with some autoimmune components, and vice versa. Cross phenotyping of patients with IAD should be heuristic and help revise the nosography and the understanding of these diseases.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
CIC Paris-Est, Hôpital PITIE SALPETRIERE, Paris, France
The family of inflammatory/autoimmune systemic diseases (IAD) represents a large group of human diseases. For most if not all of these IAD, the pathophysiological processes or exact causes remain poorly understood. Progresses in molecular understanding of these IAD have led to realize that these are not two distinct categories of diseases. Rather they form a continuum from pure inflammatory diseases to pure autoimmune diseases, encompassing a large panel of inflammatory diseases with some autoimmune components, and vice versa.
Using systems biology, the investigator aims to improve the understanding of these diseases, to identify novel genes/pathways involved, specific or across the diseases, and to discover biomarkers and potential therapeutic targets.
The investigator will study adult patients with at least one of the following IAD: Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome, Familial Mediterranean Fever (FMF), Cryopyrin-Associated Periodic Syndromes (CAPS) /Tumor Necrosis Factor-receptor Associated Periodic Syndrome (TRAPS), Vasculitis, Uveitis, Myositis, Crohn's Disease, Ulcerative colitis, Type 1 Diabetes. This panel will be completed by controls groups: healthy volunteers, and patients with arthritis (knee and/or hip) or muscular dystrophy.
The biological investigations will notably comprise: immunomics (comprehensive evaluation of peripheral blood cell subsets and serum immunoproteomics, including autoantibodies); transcriptomics; Human Leukocyte Antigen (HLA)-phenotyping; genomics; T-Cell Receptor (TCR) sequencing and microbiota studies.
After signing the informed consent, the subject attends only one visit (Day 0) during which all biological samples will be taken and all clinical information collected.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Clinical and Biological investigations
Clinical and Biological investigations
Time frame: at day 0, no follow-up
Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach
Time frame: at day 0, no follow-up
Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach
Time frame: at day 0, no follow-up
Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach
Time frame: at day 0, no follow-up
Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach
Time frame: at day 0, no follow-up
Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach
Time frame: at day 0, no follow-up
Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach
Time frame: at day 0, no follow-up
Identification of new biomarkers and potential therapeutic by multiscale analysis
Time frame: at day 0, no follow-up
Identification of new biomarkers and potential therapeutic by multiscale analysis
Time frame: at day 0, no follow-up
Identification of new biomarkers and potential therapeutic by multiscale analysis
Time frame: at day 0, no follow-up
Identification of new biomarkers and potential therapeutic by multiscale analysis
Time frame: at day 0, no follow-up
Identification of new biomarkers and potential therapeutic by multiscale analysis
Time frame: at day 0, no follow-up
Identification of new biomarkers and potential therapeutic by multiscale analysis
Time frame: at day 0, no follow-up
Identification of new biomarkers and potential therapeutic by multiscale analysis
Time frame: at day 0, no follow-up
Identification of new biomarkers and potential therapeutic by multiscale analysis
Time frame: at day 0, no follow-up
Identification of new biomarkers and potential therapeutic by multiscale analysis
Time frame: at day 0, no follow-up
Identification of new biomarkers and potential therapeutic by multiscale analysis
Time frame: at day 0, no follow-up
Identification of new biomarkers and potential therapeutic by multiscale analysis
Time frame: at day 0, no follow-up
Identification of new biomarkers and potential therapeutic by multiscale analysis
Assistance Publique - Hôpitaux de Paris
Other
Clinical and Multi-omics Cross-phenotyping of Patients With Autoimmune and Auto-inflammatory Diseases
Acronym: TRANSIMMUNOM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05730842
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Madison, Wisconsin, United States
View Trial DetailsNCT06609356
Autoimmune Diseases, Diabetes Mellitus
Nashville, Tennessee, United States
View Trial DetailsNCT07502417
Healthy Volunteer
Grayslake, Illinois, United States
View Trial DetailsNCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial Details